Avillion LLP, a drug development company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development to marketing approval, is pleased to announce that Ulf Wiinberg has been elected as Chairman of its Board of Directors.
Mr Wiinberg is Chief Executive Officer (CEO) of H. Lundbeck A/S, a position he has held since June 2008. Before joining Lundbeck, he worked at Wyeth/Lederle for 27 years, most recently as President of Wyeth Europe and Wyeth BioPharma. He is presently a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturer Association (IFPMA), Pharmaceutical Research and Manufacturers of America (PhRMA), and Dolder. In Denmark, Mr Wiinberg serves on the Industrial Policy Committee under the Confederation of Danish Industry, and he is a member of the board of directors of Alfa Laval in Sweden.
Genghis Lloyd-Harris, a non-executive director of Avillion and a Partner at Abingworth LLP, said: “On behalf of the Board of Directors, I am pleased to welcome Ulf as Avillion’s Chairman. His election represents another significant step for Avillion. Ulf’s knowledge and experience will be highly valuable as the company executes its innovative strategy and expands its profile as a late-stage drug development partner of choice.”
Ulf Wiinberg added: “Avillion is making great progress in addressing an important area of late-stage drug development; by leveraging its experienced clinical development team and financial resources, Avillion enables pharmaceutical partners to continue to advance their most important drug candidates while managing their internal resource limitations. I am delighted to join the Company as Chairman and look forward to supporting its further growth and development.”